An update on the drug safety of treating erectile dysfunction

References

• Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. 1999;84:50–56.
   PubMed Web of Science ®Google Scholar
• Johannes CB, Araujo AB, Feldman HA, et al. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. J Urol. 2000;163:460–463.
   PubMed Web of Science ®Google Scholar
• Soterio-Pires JH, Hirotsu C, Kim LJ, et al. The interaction between erectile dysfunction complaints and depression in men: a cross-sectional study about sleep, hormones and quality of life. Int J Impot Res. 2017;29:70–75.
   PubMed Web of Science ®Google Scholar
• Virag R. Intracavernous injection of papaverine for erectile failure. Lancet. 1982;2:938.
   PubMed Web of Science ®Google Scholar
• Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group. N Engl J Med. 1996;334:873–877.
   PubMed Web of Science ®Google Scholar
• Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. sildenafil study group. N Engl J Med. 1998;338:1397–1404.
   PubMed Web of Science ®Google Scholar
• Eardley I, Cartledge J. Tadalafil (Cialis) for men with erectile dysfunction. Int J Clin Pract. 2002;56:300–304.
   PubMed Web of Science ®Google Scholar
• Porst H, Rosen R, Padma-Nathan H, et al. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res. 2001;13:192–199.
   PubMed Web of Science ®Google Scholar
• Goldstein I, Young JM, Fischer J, et al. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care. 2003;26:777–783.
   PubMed Web of Science ®Google Scholar
• Wang R, Burnett AL, Heller WH, et al. Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability. J Sex Med. 2012;9:2122–2129.
   PubMed Web of Science ®Google Scholar
• Hellstrom WJG, Freier MT, Serefoglu EC, et al. A phase II, single-blind, randomized, crossover evaluation of the safety and efficacy of avanafil using visual sexual stimulation in patients with mild to moderate erectile dysfunction. BJU Int. 2013;111:137–147.
   PubMed Web of Science ®Google Scholar
• Hatzimouratidis K, Giuliano F, Moncada I, et al. EAU guidelines on erectile dysfunction,premature ejaculation, penile curvature and priapism. european association of urology guidelines. 2019. [Internet]. European Association of Urology Guidelines Office; 2019. Available from: http://uroweb.org/guideline/male-sexual-dysfunction/
   Google Scholar
• Montgomery J, Madsen C, Leroux T, et al. Utilization and prescription patterns of phosphidiesterase-5 inhibitor medications in the United States military health system. Int J Impot Res. 2018;30:300–305.
   PubMed Web of Science ®Google Scholar
• Burnett AL, Nehra A, Breau RH, et al. Erectile dysfunction: AUA guideline. J Urol. 2018;200:633–641.
   PubMed Web of Science ®Google Scholar
• Lue TF. Erectile dysfunction. N Engl J Med. 2000;342:1802–1813.
   PubMed Web of Science ®Google Scholar
• Rajfer J, Aronson WJ, Bush PA, et al. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med. 1992;326:90–94.
   PubMed Web of Science ®Google Scholar
• Corbin JD, Francis SH. Cyclic GMP phosphodiesterase-5: target of sildenafil. J Biol Chem. 1999;274:13729–13732.
   PubMed Web of Science ®Google Scholar
• Corbin JD, Francis SH. Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract. 2002;56:453–459.
   PubMed Web of Science ®Google Scholar
• Filippi S, Morelli A, Sandner P, et al. Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinology. 2007;148:1019–1029.
   PubMed Web of Science ®Google Scholar
• Porst H, Burnett A, Brock G, et al. SOP conservative (medical and mechanical) treatment of erectile dysfunction. J Sex Med. 2013;10:130–171.
   PubMed Web of Science ®Google Scholar
• Blount MA, Beasley A, Zoraghi R, et al. Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation. Mol Pharmacol. 2004;66:144–152.
   PubMed Web of Science ®Google Scholar
• Laxman S, Beavo JA. Cyclic nucleotide signaling mechanisms in trypanosomes: possible targets for therapeutic agents. Mol Interv. 2007;7:203–215.
   PubMedGoogle Scholar
• Zhang X, Feng Q, Cote RH. Efficacy and selectivity of phosphodiesterase-targeted drugs to inhibit photoreceptor phosphodiesterase (PDE6) in retinal photoreceptors. Invest Ophthalmol Vis Sci. 2005;46:3060–3066.
   PubMed Web of Science ®Google Scholar
• Morales A, Gingell C, Collins M, et al. Clinical safety of oral sildenafil citrate (VIAGRA) in the treatment of erectile dysfunction. Int J Impot Res. 1998;10:69–73; discussion 73–74.
   PubMed Web of Science ®Google Scholar
• Hellstrom WJG, Gittelman M, Karlin G, et al. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl. 2002;23:763–771.
   PubMed Web of Science ®Google Scholar
• Carson CC, Rajfer J, Eardley I, et al. The efficacy and safety of tadalafil: an update. BJU Int. 2004;93:1276–1281.
   PubMed Web of Science ®Google Scholar
• Hellstrom WJG, Gittelman M, Karlin G, et al. Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. Urology. 2003;61:8–14.
   PubMed Web of Science ®Google Scholar
• Yuan J, Zhang R, Yang Z, et al. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis. Eur Urol. 2013;63:902–912.
   PubMed Web of Science ®Google Scholar
• Chen L, Staubli SEL, Schneider MP, et al. Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction: a trade-off network meta-analysis. Eur Urol. 2015;68:674–680.
   PubMed Web of Science ®Google Scholar
• Ventimiglia E, Capogrosso P, Montorsi F, et al. The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction. Expert Opin Drug Saf. 2016;15:141–152.
   PubMed Web of Science ®Google Scholar
• Brock GB, McMahon CG, Chen KK, et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol. 2002;168:1332–1336.
   PubMed Web of Science ®Google Scholar
• Goldstein I, McCullough AR, Jones LA, et al. A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction. J Sex Med. 2012;9:1122–1133.
   PubMed Web of Science ®Google Scholar
• Zhao C, Kim SW, Yang DY, et al. Efficacy and safety of avanafil for treating erectile dysfunction: results of a multicentre, randomized, double-blind, placebo-controlled trial. BJU Int. 2012;110:1801–1806.
   PubMed Web of Science ®Google Scholar
• Belkoff LH, McCullough A, Goldstein I, et al. An open-label, long-term evaluation of the safety, efficacy and tolerability of avanafil in male patients with mild to severe erectile dysfunction. Int J Clin Pract. 2013;67:333–341.
   PubMed Web of Science ®Google Scholar
• Hellstrom WJG, Kaminetsky J, Belkoff LH, et al. Efficacy of avanafil 15 minutes after dosing in men with erectile dysfunction: a randomized, double-blind, placebo controlled study. J Urol. 2015;194:485–492.
   PubMed Web of Science ®Google Scholar
• Tracqui A, Miras A, Tabib A, et al. Fatal overdosage with sildenafil citrate (Viagra): first report and review of the literature. Hum Exp Toxicol. 2002;21:623–629.
   PubMed Web of Science ®Google Scholar
• Finley DS, Lugo B, Ridgway J, et al. Fatal variceal rupture after sildenafil use: report of a case. Curr Surg. 2005;62:55–56.
   PubMedGoogle Scholar
• Giannetta E, Feola T, Gianfrilli D, et al. Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials. BMC Med. 2014;12:185.
   PubMed Web of Science ®Google Scholar
• Lowe G, Costabile RA. 10-Year analysis of adverse event reports to the food and drug administration for phosphodiesterase type-5 inhibitors. J Sex Med. 2012;9:265–270.
   PubMed Web of Science ®Google Scholar
• Nehra A, Jackson G, Miner M, et al. The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc. 2012;87:766–778.
   PubMed Web of Science ®Google Scholar
• Pofi R, Gianfrilli D, Badagliacca R, et al. Everything you ever wanted to know about phosphodiesterase 5 inhibitors and the heart (but never dared ask): how do they work? J. Endocrinol Invest. 2016;39:131–142.
   PubMed Web of Science ®Google Scholar
• Guazzi M, Vicenzi M, Arena R, et al. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail. 2011;4:8–17.
   PubMed Web of Science ®Google Scholar
• Anderson SG, Hutchings DC, Woodward M, et al. Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality. Heart. 2016;102:1750–1756.
   PubMed Web of Science ®Google Scholar
• Andersson DP, Trolle Lagerros Y, Grotta A, et al. Association between treatment for erectile dysfunction and death or cardiovascular outcomes after myocardial infarction. Heart. 2017;103:1264–1270.
   PubMed Web of Science ®Google Scholar
• Hackett G, Kirby M, Wylie K, et al. British society for sexual medicine guidelines on the management of erectile dysfunction in men-2017. J Sex Med. 2018;15:430–457.
   PubMed Web of Science ®Google Scholar
• Mukherjee B, Shivakumar T. A case of sensorineural deafness following ingestion of sildenafil. J Laryngol Otol. 2007;121:395–397.
   PubMed Web of Science ®Google Scholar
• Maddox PT, Saunders J, Chandrasekhar SS. Sudden hearing loss from PDE‐5 inhibitors: a possible cellular stress etiology. Laryngoscope. 2009;119:1586–1589.
   PubMed Web of Science ®Google Scholar
• Khan AS, Sheikh Z, Khan S, et al. Viagra deafness–sensorineural hearing loss and phosphodiesterase-5 inhibitors. Laryngoscope. 2011;121:1049–1054.
   PubMed Web of Science ®Google Scholar
• Skeith L, Yamashita C, Mehta S, et al. Sildenafil and furosemide associated ototoxicity: consideration of drug-drug interactions, synergy, and broader clinical relevance. J Popul Ther Clin Pharmacol. 2013;20:e128–131.
   PubMedGoogle Scholar
• Thakur JS, Thakur S, Sharma DR, et al. Hearing loss with phosphodiesterase-5 inhibitors: a prospective and objective analysis with tadalafil. Laryngoscope. 2013;123:1527–1530.
   PubMed Web of Science ®Google Scholar
• Hong BN, Yi TH, Kim SY, et al. High dosage sildenafil induces hearing impairment in mice. Biol Pharm Bull. 2008;31:1981–1984.
   PubMed Web of Science ®Google Scholar
• Bakir S, Firat U, Gün R, et al. Histopathologic results of long-term sildenafil administration on rat inner ear. Am J Otolaryngol. 2012;33:667–672.
   PubMed Web of Science ®Google Scholar
• Jaumann M, Dettling J, Gubelt M, et al. cGMP-Prkg1 signaling and Pde5 inhibition shelter cochlear hair cells and hearing function. Nat Med. 2012;18:252–259.
   PubMed Web of Science ®Google Scholar
• Mahmood G, Mei Z, Hojjat H, et al. Therapeutic effect of sildenafil on blast-induced tinnitus and auditory impairment. Neuroscience. 2014;269:367–382.
   PubMed Web of Science ®Google Scholar
• Liang Y, Zhang S, Zhang X. [Effect of sildenafil on morphology to noise-induced hearing loss in guinea pigs]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2015;29:1216–1220.
   PubMedGoogle Scholar
• Au A, Stuyt JG, Chen D, et al. Ups and downs of Viagra: revisiting ototoxicity in the mouse model. PLoS ONE. 2013;8:e79226.
   PubMed Web of Science ®Google Scholar
• Laties A, Sharlip I. Ocular safety in patients using sildenafil citrate therapy for erectile dysfunction. J Sex Med. 2006;3:12–27.
   PubMed Web of Science ®Google Scholar
• Roessler G, Vobig M, Walter P, et al. Ocular side effects of Levitra® (vardenafil) - results of a double-blind crossover study in healthy male subjects. Drug Des Devel Ther. 2019;13:37–43.
   PubMed Web of Science ®Google Scholar
• Kerr NM, Danesh-Meyer HV. Phosphodiesterase inhibitors and the eye. Clin Exp Ophthalmol. 2009;37:514–523.
   PubMed Web of Science ®Google Scholar
• Gorkin L, Hvidsten K, Sobel R, et al. Sildenafil citrate use and the incidence of nonarteritic anterior ischemic optic neuropathy. Int J Clin Pract. 2006;60:500–503.
   PubMed Web of Science ®Google Scholar
• Miller NR, Arnold AC. Current concepts in the diagnosis, pathogenesis and management of nonarteritic anterior ischaemic optic neuropathy. Eye (Lond). 2015;29:65–79.
   PubMed Web of Science ®Google Scholar
• Pomeranz HD. The relationship between phosphodiesterase-5 inhibitors and nonarteritic anterior ischemic optic neuropathy. J Neuroophthalmol. 2016;36:193–196.
   PubMed Web of Science ®Google Scholar
• Nathoo NA, Etminan M, Mikelberg FS. Association between phosphodiesterase-5 inhibitors and nonarteritic anterior ischemic optic neuropathy. J Neuroophthalmol. 2015;35:12–15.
   PubMed Web of Science ®Google Scholar
• Campbell UB, Walker AM, Gaffney M, et al. Acute nonarteritic anterior ischemic optic neuropathy and exposure to phosphodiesterase type 5 inhibitors. J Sex Med. 2015;12:139–151.
   PubMed Web of Science ®Google Scholar
• Flahavan EM, Li H, Gupte-Singh K, et al. Prospective case-crossover study investigating the possible association between nonarteritic anterior ischemic optic neuropathy and phosphodiesterase type 5 inhibitor exposure. Urology. 2017;105:76–84.
   PubMed Web of Science ®Google Scholar
• Matthews NH, Li W-Q, Qureshi AA. Epidemiology of Melanoma. In: Ward WH, Farma JM, et al., editors Cutaneous melanoma: etiology and therapy [Internet]. Brisbane (AU): Codon Publications; 2017. [cited 2019 Jun 30]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK481862/
   Google Scholar
• Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma in the era of molecular profiling. Lancet. 2009;374:362–365.
   PubMed Web of Science ®Google Scholar
• Arozarena I, Sanchez-Laorden B, Packer L, et al. Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A. Cancer Cell. 2011;19:45–57.
   PubMed Web of Science ®Google Scholar
• Li W-Q, Qureshi AA, Robinson KC, et al. Sildenafil use and increased risk of incident melanoma in US men: a prospective cohort study. JAMA Intern Med. 2014;174:964–970.
   PubMed Web of Science ®Google Scholar
• Lian Y, Yin H, Pollak MN, et al. Phosphodiesterase type 5 inhibitors and the risk of melanoma skin cancer. Eur Urol. 2016;70:808–815.
   PubMed Web of Science ®Google Scholar
• Matthews A, Langan SM, Douglas IJ, et al. Phosphodiesterase type 5 inhibitors and risk of malignant melanoma: matched cohort study using primary care data from the UK Clinical practice research datalink. PLoS Med. 2016;13:e1002037.
   PubMed Web of Science ®Google Scholar
• Loeb S, Folkvaljon Y, Lambe M, et al. Use of phosphodiesterase type 5 inhibitors for erectile dysfunction and risk of malignant melanoma. JAMA. 2015;313:2449–2455.
   PubMed Web of Science ®Google Scholar
• Boor P, Nardone B, Polisetty S, et al. Melanoma in men treated with PDE5A inhibitors: a report from the RADAR (Research on Adverse Drug Events And Reports) project. JAAD. 2016;74:AB190.
   Web of Science ®Google Scholar
• Pottegård A, Schmidt SAJ, Olesen AB, et al. Use of sildenafil or other phosphodiesterase inhibitors and risk of melanoma. Br J Cancer. 2016;115:895–900.
   PubMed Web of Science ®Google Scholar
• Wang J, Shen Y, Wang J, et al. Relation of phosphodiesterase type 5 inhibitors and malignant melanoma: a meta-analysis and systematic review. Oncotarget. 2017;8:46461–46467.
   PubMedGoogle Scholar
• Loeb S, Ventimiglia E, Salonia A, et al. Meta-analysis of the association between phosphodiesterase inhibitors (PDE5Is) and risk of melanoma. J Natl Cancer Inst. 2017;109.
   PubMedGoogle Scholar
• Deng T, Duan X, Liu B, et al. Association between phosphodiesterase type 5 inhibitors use and risk of melanoma: a meta-analysis. Neoplasma. 2018;65:216–221.
   PubMed Web of Science ®Google Scholar
• Feng S, Zhou L, Liu Q, et al. Are phosphodiesterase type 5 inhibitors associated with increased risk of melanoma?: a systematic review and meta-analysis. Medicine (Baltimore). 2018;97:e9601.
   PubMed Web of Science ®Google Scholar
• Han X, Han Y, Zheng Y, et al. Use of phosphodiesterase type 5 inhibitors and risk of melanoma: a meta-analysis of observational studies. Onco Targets Ther. 2018;11:711–720.
   PubMed Web of Science ®Google Scholar
• Hill AB. The environment and disease: association or causation? . Proc R Soc Med. 1965;58:295–300.
   PubMed Web of Science ®Google Scholar
• Michl U, Molfenter F, Graefen M, et al. Use of phosphodiesterase type 5 inhibitors may adversely impact biochemical recurrence after radical prostatectomy. J Urol. 2015;193:479–483.
   PubMed Web of Science ®Google Scholar
• Gallina A, Bianchi M, Gandaglia G, et al. A detailed analysis of the association between postoperative phosphodiesterase type 5 inhibitor use and the risk of biochemical recurrence after radical prostatectomy. Eur Urol. 2015;68:750–753.
   PubMed Web of Science ®Google Scholar
• Loeb S, Folkvaljon Y, Robinson D, et al. Phosphodiesterase type 5 inhibitor use and disease recurrence after prostate cancer treatment. Eur Urol. 2016;70:824–828.
   PubMed Web of Science ®Google Scholar
• Jo JK, Kim K, Lee SE, et al. Phosphodiesterase type 5 inhibitor use following radical prostatectomy is not associated with an increased risk of biochemical recurrence. Ann Surg Oncol. 2016;23:1760–1767.
   PubMed Web of Science ®Google Scholar
• Broderick GA, Kadioglu A, Bivalacqua TJ, et al. Priapism: pathogenesis, epidemiology, and management. J Sex Med. 2010;7:476–500.
   PubMed Web of Science ®Google Scholar
• Giuliano F, Jackson G, Montorsi F, et al. Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database. Int J Clin Pract. 2010;64:240–255.
   PubMed Web of Science ®Google Scholar
• Burnett AL, Bivalacqua TJ, Champion HC, et al. Feasibility of the use of phosphodiesterase type 5 inhibitors in a pharmacologic prevention program for recurrent priapism. J Sex Med. 2006;3:1077–1084.
   PubMed Web of Science ®Google Scholar
• Champion HC, Bivalacqua TJ, Takimoto E, et al. Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism. Proc Natl Acad Sci USA. 2005;102:1661–1666.
   PubMed Web of Science ®Google Scholar
• Khalaf MAM, MF A, HM E-F. Effects of chronic tadalafil use on the testes and sperm parameters of old albino rats. Andrologia. 2012;44(Suppl 1):370–375.
   PubMedGoogle Scholar
• Eid AA, Badr El Dine FMM, Nabil IM. Histopathologic and ultrastructural changes in seminiferous tubules of adult male albino rats following daily administration of different doses of tadalafil. Urology. 2016;90:89–96.
   PubMed Web of Science ®Google Scholar
• Fawcett L, Baxendale R, Stacey P, et al. Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. Proc Natl Acad Sci USA. 2000;97:3702–3707.
   PubMed Web of Science ®Google Scholar
• Hellstrom WJG, Overstreet JW, Yu A, et al. Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones. J Urol. 2003;170:887–891.
   PubMed Web of Science ®Google Scholar
• Hellstrom WJG, Gittelman M, Jarow J, et al. An evaluation of semen characteristics in men 45 years of age or older after daily dosing with tadalafil 20mg: results of a multicenter, randomized, double-blind, placebo-controlled, 9-month study. Eur Urol. 2008;53:1058–1065.
   PubMed Web of Science ®Google Scholar
• Scherzer ND, Le TV, Hellstrom WJG. Sildenafil’s impact on male infertility: what has changed in 20 years? Int J Impot Res. 2019;31:71–73.
   PubMed Web of Science ®Google Scholar
• Du Plessis SS, de Jongh PS, Franken DR. Effect of acute in vivo sildenafil citrate and in vitro 8-bromo-cGMP treatments on semen parameters and sperm function. Fertil Steril. 2004;81:1026–1033.
   PubMed Web of Science ®Google Scholar
• Bischoff E. Potency, selectivity, and consequences of nonselectivity of PDE inhibition. Int J Impot Res. 2004;16(Suppl 1):S11–14.
   PubMed Web of Science ®Google Scholar
• Porst H. IC351 (tadalafil, Cialis): update on clinical experience. Int J Impot Res. 2002;14(Suppl 1):S57–64.
   PubMedGoogle Scholar
• Yafi FA, Sharlip ID, Becher EF. Update on the safety of phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction. Sex Med Rev. 2018;6:242–252.
   PubMed Web of Science ®Google Scholar
• Wills BK, Albinson C, Wahl M, et al. Sildenafil citrate ingestion and prolonged priapism and tachycardia in a pediatric patient. Clin Toxicol (Phila). 2007;45:798–800.
   PubMed Web of Science ®Google Scholar
• Oh D-J. Sildenafil overdose can cause rhabdomyolysis and subjective visual perception changes. Nephrology (Carlton). 2014;19:258.
   PubMedGoogle Scholar
• Matheeussen V, Maudens KE, Anseeuw K, et al. A non-fatal self-poisoning attempt with sildenafil. J Anal Toxicol. 2015;39:572–576.
   PubMed Web of Science ®Google Scholar
• Ernst E, Pittler MH. Yohimbine for erectile dysfunction: a systematic review and meta-analysis of randomized clinical trials. J Urol. 1998;159:433–436.
   PubMed Web of Science ®Google Scholar
• Chen J, Wollman Y, Chernichovsky T, et al. Effect of oral administration of high-dose nitric oxide donor L-arginine in men with organic erectile dysfunction: results of a double-blind, randomized, placebo-controlled study. BJU Int. 1999;83:269–273.
   PubMed Web of Science ®Google Scholar
• Kearney T, Tu N, Haller C. Adverse drug events associated with yohimbine-containing products: a retrospective review of the california poison control system reported cases. Ann Pharmacother. 2010;44:1022–1029.
   PubMed Web of Science ®Google Scholar
• Nakaki T, Hishikawa K, Suzuki H, et al. L-arginine-induced hypotension. Lancet. 1990;336:696.
   PubMed Web of Science ®Google Scholar
• Brindley GS. Cavernosal alpha-blockade: a new technique for investigating and treating erectile impotence. Br J Psychiatry. 1983;143:332–337.
   PubMed Web of Science ®Google Scholar
• Virag R, Adaikan PG. Effects of prostaglandin E1 on penile erection and erectile failure. J Urol. 1987;137:1010.
   PubMed Web of Science ®Google Scholar
• Sikka SC, Hellstrom WJG, Brock G, et al. Standardization of vascular assessment of erectile dysfunction. J Sex Med. 2013;10:120–129.
   PubMed Web of Science ®Google Scholar
• Virag R, Frydman D, Legman M, et al. Intracavernous injection of papaverine as a diagnostic and therapeutic method in erectile failure. Angiology. 1984;35:79–87.
   PubMed Web of Science ®Google Scholar
• Kilic M, Serefoglu EC, Ozdemir AT, et al. The actual incidence of papaverine-induced priapism in patients with erectile dysfunction following penile colour Doppler ultrasonography. Andrologia. 2010;42:1–4.
   PubMed Web of Science ®Google Scholar
• Brown SL, Haas CA, Koehler M, et al. Hepatotoxicity related to intracavernous pharmacotherapy with papaverine. Urology. 1998;52:844–847.
   PubMed Web of Science ®Google Scholar
• Virag R, Shoukry K, Floresco J, et al. Intracavernous self-injection of vasoactive drugs in the treatment of impotence: 8-year experience with 615 cases. J Urol. 1991;145:287–292; discussion 292–293.
   PubMed Web of Science ®Google Scholar
• Traish A, Gupta S, Gallant C, et al. Phentolamine mesylate relaxes penile corpus cavernosum tissue by adrenergic and non-adrenergic mechanisms. Int J Impot Res. 1998;10:215–223.
   PubMed Web of Science ®Google Scholar
• Hatzimouratidis K, Salonia A, Adaikan G, et al. Pharmacotherapy for erectile dysfunction: recommendations from the fourth international consultation for sexual medicine (ICSM 2015). J Sex Med. 2016;13:465–488.
   PubMed Web of Science ®Google Scholar
• Belew D, Klaassen Z, Lewis RW. Intracavernosal injection for the diagnosis, evaluation, and treatment of erectile dysfunction: a review. Sex Med Rev. 2015;3:11–23.
   PubMedGoogle Scholar
• Lee SW, Wang HZ, Zhao W, et al. Prostaglandin E1 activates the large-conductance KCa channel in human corporal smooth muscle cells. Int J Impot Res. 1999;11:189–199.
   PubMed Web of Science ®Google Scholar
• Hanchanale V, Eardley I. Alprostadil for the treatment of impotence. Expert Opin Pharmacother. 2014;15:421–428.
   PubMed Web of Science ®Google Scholar
• Roy AC, Adaikan PG, Sen DK, et al. Prostaglandin 15-hydroxydehydrogenase activity in human penile corpora cavernosa and its significance in prostaglandin-mediated penile erection. Br J Urol. 1989;64:180–182.
   PubMedGoogle Scholar
• Seyam R, Mohamed K, Akhras AA, et al. A prospective randomized study to optimize the dosage of trimix ingredients and compare its efficacy and safety with prostaglandin E1. Int J Impot Res. 2005;17:346–353.
   PubMed Web of Science ®Google Scholar
• Vieillard V, Eychenne N, Astier A, et al. Physicochemical stability study of a new Trimix formulation for treatment of erectile dysfunction. Ann Pharm Fr. 2013;71:358–363.
   PubMedGoogle Scholar
• Montorsi F, Guazzoni G, Bergamaschi F, et al. Clinical reliability of multi-drug intracavernous vasoactive pharmacotherapy for diabetic impotence. Acta Diabetol. 1994;31:1–5.
   PubMed Web of Science ®Google Scholar
• Sogari PR, Telöken C, Souto CA. Atropine role in the pharmacological erection test: study of 228 patients. J Urol. 1997;158:1760–1763.
   PubMed Web of Science ®Google Scholar
• Moncada I, Martinez-Salamanca J, Ruiz-Castañe E, et al. Combination therapy for erectile dysfunction involving a PDE5 inhibitor and alprostadil. Int J Impot Res. 2018;30:203–208.
   PubMed Web of Science ®Google Scholar
• O’Kane D, Gibson L, Du Plessis J, et al. Delivery of intracavernosal therapies using needle-free injection devices. Int J Impot Res. 2017;29:225–228.
   PubMed Web of Science ®Google Scholar
• Porst H. The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience. J Urol. 1996;155:802–815.
   PubMed Web of Science ®Google Scholar
• He L, Wen J, Jiang X, et al. Long-term efficacy and safety of self-intracavernous injection of prostaglandin E1 for treatment of erectile dysfunction in China. Andrologia. 2011;43:208–212.
   PubMed Web of Science ®Google Scholar
• Porst H. Transurethral alprostadil with MUSE (medicated urethral system for erection) vs intracavernous alprostadil–a comparative study in 103 patients with erectile dysfunction. Int J Impot Res. 1997;9:187–192.
   PubMed Web of Science ®Google Scholar
• Costabile RA, Spevak M, Fishman IJ, et al. Efficacy and safety of transurethral alprostadil in patients with erectile dysfunction following radical prostatectomy. J Urol. 1998;160:1325–1328.
   PubMed Web of Science ®Google Scholar
• Padma-Nathan H, Yeager JL. An integrated analysis of alprostadil topical cream for the treatment of erectile dysfunction in 1732 patients. Urology. 2006;68:386–391.
   PubMed Web of Science ®Google Scholar
• Wolka AM, Rytting JH, Reed BL, et al. The interaction of the penetration enhancer DDAIP with a phospholipid model membrane. Int J Pharm. 2004;271:5–10.
   PubMedGoogle Scholar
• Rooney M, Pfister W, Mahoney M, et al. Long-term, multicenter study of the safety and efficacy of topical alprostadil cream in male patients with erectile dysfunction. J Sex Med. 2009;6:520–534.
   PubMed Web of Science ®Google Scholar
• Cai T, Palumbo F, Liguori G, et al. The intra-meatal application of alprostadil cream (Vitaros®) improves drug efficacy and patient’s satisfaction: results from a randomized, two-administration route, cross-over clinical trial. Int J Impot Res. 2019;31:119–125.
   PubMed Web of Science ®Google Scholar
• Prescribing information [Internet]. Vitaros. [cited 2019 Jun 30]. Available from: http://www.vitaros.co.uk/prescribing-information/.
   Google Scholar